Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Natural Remedies

Parkinson's Disease: Novel Drug Discovery Tool Could Identify Promising New Therapies
Researchers funded by the National Institutes of Health have turned simple baker"s yeast into a virtual army of medicinal chemists capable of rapidly searching for drugs to treat Parkinson"s disease.
generic viagra online
Greater Risks For Patients With Heart Attacks Posed By Crowded Emergency Departments
Patients with heart attacks and other forms of chest pain are three to five times more likely to experience serious complications after hospital admission when they are treated in a crowded emergency department (ED), according to a new study published in the journal Academic Emergency Medicine. The authors say that this dramatic difference in rates of serious complications underscores the need for action on the part of hospital administrators, policymakers and emergency physicians to find solutions to what has been termed "a national public health problem." More than six million patients per year come to U.S. emergency departments with chest pain.
News of the day
Response To Healthcare For London Consultation Results
Joe Korner, Director of Communications at The Stroke Association said:
Medical Devices

Baxter To Acquire Continuous Renal Replacement Therapy Business From Edwards Lifesciences

Baxter International Inc. (NYSE:BAX) announced today a definitive agreement with Edwards Lifesciences Corporation (NYSE:EW) under which Baxter will acquire certain assets related to Edwards" hemofiltration product line, also known as Continuous Renal Replacement Therapy (CRRT). The transaction is expected to close in the third quarter of 2009, pending regulatory approvals. Under the terms of the agreement, Baxter will provide Edwards an initial cash payment of approximately $56 million upon the close of the transaction. Additionally, Baxter will receive transition services from Edwards and is expected to pay Edwards up to an additional $9 million based on revenue objectives expected to be achieved over the next two years. The impact of this transaction is immaterial to Baxter"s financial results for 2009. Hemofiltration, or CRRT, mimics the function of the kidneys 24 hours a day for patients with life-threatening kidney injuries or edema (fluid overload). CRRT provides a method of continuous yet adjustable fluid removal that can gradually remove excess fluid and waste products that build up with the acute impairment of kidney function, and is usually administered in an intensive care setting in the hospital. Baxter currently supplies solutions used in CRRT treatment globally, and is the exclusive distributor of Edwards" product in China, Latin America and the United States. Approximately 60 employees will be joining Baxter from Edwards as part of this transaction. "As an experienced leader in dialysis therapies including CRRT, this acquisition represents an extension of our existing Renal business, and demonstrates our commitment to save and sustain the lives of patients with acute kidney injuries," said Bruce McGillivray, corporate vice president and president of Baxter"s Renal business. "This acquisition expands Baxter"s existing CRRT business, which is predominantly in the United States and China, into new markets such as Europe and Australia." Baxter International Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009